Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Drugs in R&D|November 6, 2021
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV InfectionSneha V Gupta, Marie C Fanget, Christopher MacLauchlin, et al.Antimicrobial Agents and Chemotherapy|February 15, 2017
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy SubjectsErik Mogalian, Polina German, Brian P Kearney, et al.Journal of Pharmaceutical Sciences|April 23, 2008
Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitorRitesh Sanghvi, Erik Mogalian, Stephen G Machatha, et al.Clinical Pharmacokinetics|March 10, 2018
Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic ImpairmentErik Mogalian, Diana M Brainard, Anu Osinusi, et al.Antimicrobial Agents and Chemotherapy|February 20, 2024
A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illnessDavid Plotnik, Jennifer E Sager, Madhukar Aryal, et al.Clinical Pharmacology and Therapeutics|December 13, 2024
Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection SitesAsma El-Zailik, Jennifer Sager, Yasmin Sánchez-Pearson, et al.CPT: Pharmacometrics & Systems Pharmacology|March 16, 2023
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19Jennifer E Sager, Asma El-Zailik, Julie Passarell, et al.Antiviral Therapy|August 9, 2014
Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis CEric Lawitz, Daniel Gruener, Thomas Marbury, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2017
Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 StudyDavid Wyles, Norbert Bräu, Shyam Kottilil, et al.The New England Journal of Medicine|October 27, 2021
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody SotrovimabAnil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al.Pageof 3